Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.
J Immunother
; 47(7): 258-262, 2024 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-38545827
ABSTRACT
Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nivolumabe
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article